WillScot (WSC) Is At $12.25 Formed Wedge; Iguana Healthcare Management Upped Immunomedics (IMMU) Position By $2.28 Million

March 7, 2018 - By Martha Paddon

Iguana Healthcare Management Llc increased Immunomedics Inc (IMMU) stake by 53.85% reported in 2017Q3 SEC filing. Iguana Healthcare Management Llc acquired 175,000 shares as Immunomedics Inc (IMMU)’s stock rose 37.64%. The Iguana Healthcare Management Llc holds 500,000 shares with $6.99M value, up from 325,000 last quarter. Immunomedics Inc now has $2.91 billion valuation. The stock increased 0.81% or $0.14 during the last trading session, reaching $17.53. About 2.07 million shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since March 7, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

WillScot Corporation (WSC) formed wedge down with $11.64 target or 5.00% below today’s $12.25 share price. WillScot Corporation (WSC) has $1.04B valuation. The stock decreased 2.00% or $0.25 during the last trading session, reaching $12.25. About 350,727 shares traded or 85.43% up from the average. WillScot Corporation (NASDAQ:WSC) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.58, from 1.65 in 2017Q2. It turned negative, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Manufacturers Life The invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). First Light Asset Mgmt Ltd Company owns 1.31M shares. Fny Managed Accounts Limited Liability has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 400 shares. Ecor1 Cap Limited Liability Corp holds 5.33% or 2.86M shares in its portfolio. Chicago Equity Prns Limited Liability Com holds 0.14% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 323,320 shares. Fmr Ltd Liability Corp accumulated 5.50 million shares or 0.01% of the stock. Jane Street Limited Liability Corporation owns 22,164 shares. Quantitative Systematic Strategies Limited Liability Company holds 10,192 shares. Rhenman And Prns Asset Ab reported 500,000 shares or 0.89% of all its holdings. Sei Invs has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 3,318 shares. Driehaus Mngmt Limited Liability Corp invested in 0.43% or 785,339 shares. Dafna Cap Management Lc holds 4% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 460,451 shares. Financial Bank Of Ny Mellon holds 681,419 shares. 2,000 were accumulated by Advisory Ntwk Lc. Fred Alger Inc owns 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 14,000 shares.

Iguana Healthcare Management Llc decreased Merck & Co Inc (NYSE:MRK) stake by 5,000 shares to 75,000 valued at $4.80M in 2017Q3. It also reduced Aetna Inc New (NYSE:AET) stake by 4,000 shares and now owns 28,500 shares. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) was reduced too.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Wednesday, December 6. On Monday, July 24 the stock rating was maintained by Cowen & Co with “Buy”. The rating was downgraded by Wells Fargo on Friday, December 4 to “Market Perform”. Jefferies reinitiated Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, October 6 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Wednesday, December 6. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. The company was maintained on Thursday, August 17 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Monday, October 9 by Jefferies. As per Tuesday, June 21, the company rating was downgraded by Wells Fargo. Jefferies upgraded Immunomedics, Inc. (NASDAQ:IMMU) rating on Friday, May 6. Jefferies has “Buy” rating and $5 target.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: